The Science
How fetomaternal microchimerism becomes a scalable IV-deliverable cell therapy for brain repair.
The Science
TET Therapeutics is built on fetomaternal microchimerism, a well-documented biological phenomenon in which fetal stem cells cross the blood-brain barrier during pregnancy and home to sites of maternal brain injury via the CCL2/CCR2 chemoattractant axis. We are engineering this natural repair mechanism and other therapeutically valuable properties of fetomaternal microchimeric stem cells into a scalable, IV-deliverable cell therapy.
Why IV delivery?
Competing cell therapies for brain repair require direct surgical injection into the brain, costing $110,000–$260,000 per patient in surgical and hospitalization costs alone. IV delivery eliminates that entirely, enabling outpatient administration and dramatically expanding access. It also enables distributed manufacturing and a fundamentally different cost structure.
001
CCL2/CCR2 Axis
Validated chemoattractant mechanism driving fetal cell recruitment to maternal brain injury sites
002
Myeloid Lineage
Brain-homing FMC cells are CD34⁺CD11b⁺CCR2-high — myeloid, not MSC
003
Surface Markers
MMP14, MCAM, KCNQ4, CLDN6, F3 identify therapeutically relevant populations
004
IV Delivery
Outpatient infusion vs. invasive brain surgery and hospitalization, costing up to $200,000
005
TBI → Brain Repair
TBI is the beachhead. Platform extends to neurodegeneration, depression, and brain replacement
006
De-risked Biology
Not a hypothesis — fetal cell trafficking is published, peer-reviewed, and reproducible
007
Syncytin
Potential role in fetal cell implantation and persistence — active area of investigation
Help us build TET Tx
We're seeking collaborators, advisors, and early-stage funding. Let's talk.